After taking it on the chin for previously reporting Bayesian estimates, actual 2-year data from the EVOLUT Low Risk trial confirm that transcatheter aortic valve replacement (TAVR) is noninferior to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results